Rep. Gilbert Ray Cisneros, Jr. Buys STERIS plc (NYSE:STE) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of STERIS plc (NYSE:STE). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on May 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of SoftBank Group (OTCMKTS:SFTBF) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 5/29/2026.
• Sold $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Independent Bank (NASDAQ:INDB) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Arcutis Biotherapeutics (NASDAQ:ARQT) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of HealthEquity (NASDAQ:HQY) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Boston Scientific (NYSE:BSX) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Perella Weinberg Partners (NASDAQ:PWP) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Cooper Companies (NASDAQ:COO) on 5/29/2026.
• Purchased $1,001 – $15,000 in shares of Ligand Pharmaceuticals (NASDAQ:LGND) on 5/29/2026.

STERIS Trading Down 2.4%

STE traded down $5.17 during trading on Wednesday, reaching $207.71. 784,310 shares of the company’s stock were exchanged, compared to its average volume of 798,985. STERIS plc has a one year low of $195.14 and a one year high of $269.44. The company has a current ratio of 2.09, a quick ratio of 1.54 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $20.27 billion, a PE ratio of 26.19 and a beta of 0.93. The firm has a fifty day moving average price of $216.83 and a two-hundred day moving average price of $238.33.

STERIS (NYSE:STE) last posted its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the previous year, the firm earned $2.74 earnings per share. The company’s revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities research analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date of this dividend is Monday, June 8th. STERIS’s payout ratio is presently 31.78%.

Insiders Place Their Bets

In related news, Director Richard C. Breeden sold 1,481 shares of the business’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total transaction of $310,284.31. Following the transaction, the director owned 38,964 shares in the company, valued at $8,163,347.64. The trade was a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel A. Carestio sold 3,054 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total transaction of $655,510.56. Following the transaction, the chief executive officer owned 65,021 shares in the company, valued at approximately $13,956,107.44. The trade was a 4.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,909 shares of company stock worth $1,257,083 in the last quarter. 1.07% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Board of the Pension Protection Fund acquired a new position in shares of STERIS during the 4th quarter valued at $25,000. Western Wealth Management LLC acquired a new position in shares of STERIS during the 1st quarter valued at $25,000. Harbor Investment Advisory LLC lifted its position in shares of STERIS by 115.4% during the 4th quarter. Harbor Investment Advisory LLC now owns 112 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 60 shares during the period. Activest Wealth Management lifted its position in shares of STERIS by 423.8% during the 4th quarter. Activest Wealth Management now owns 110 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 89 shares during the period. Finally, Measured Wealth Private Client Group LLC acquired a new position in shares of STERIS during the 4th quarter valued at $28,000. Institutional investors and hedge funds own 94.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on STE shares. Piper Sandler reaffirmed an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday. KeyCorp reduced their price objective on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.